Journal article

Macrophage-derived oncostatin M contributes to human and mouse neurogenic heterotopic ossifications

Frederic Torossian, Bernadette Guerton, Adrienne Anginot, Kylie A Alexander, Christophe Desterke, Sabrina Soave, Hsu-Wen Tseng, Nassim Arouche, Laetitia Boutin, Irina Kulina, Marjorie Salga, Beulah Jose, Allison R Pettit, Denis Clay, Nathalie Rochet, Erica Vlachos, Guillaume Genet, Charlotte Debaud, Philippe Denormandie, Francois Genet Show all

JCI Insight | AMER SOC CLINICAL INVESTIGATION INC | Published : 2017

Grants

Awarded by French Government Defense Procurement and Technology Agency (DGA)


Awarded by National Health and Medical Research Council of Australia (NHMRC)


Awarded by Assistant Secretary of Defense for Health Affairs through Spinal Cord Injury Research Program from the US Department of Defence


Awarded by INSERM


Awarded by NHMRC


Funding Acknowledgements

This research was funded by project grant 1101620 from the French Government Defense Procurement and Technology Agency (DGA; to FT, FG, JJL, and MCLBK), project grant APP1101620 from the National Health and Medical Research Council of Australia (NHMRC to JPL, FG, and NAS), and by the Assistant Secretary of Defense for Health Affairs through Spinal Cord Injury Research Program under award no. W81XWH-15-1-0606 from the US Department of Defence; UMR-S-MD1197 is partly funded by INSERM. JPL is supported by research fellowship APP1044091 from the NHMRC. The Translational Research Institute is partly funded by the Federal Government of Australia. The authors are indebted to P. Mauduit (Inserm UMR-S-MD1197, Paul Brousse Hospital, Villejuif, France) for his scientific and technical advices concerning Western blot analyses. The authors greatly acknowledge the technical assistance of "Cochin HistIM Facility" (Paris, France) and D. Burgot (Polyclinique de Blois, La Chaussee-Saint-Victor, France) for supplying human BM samples. The authors also acknowledge the scientific and technical assistance of the Translational Research Institute Preclinical Imaging Facility, which is supported by Therapeutic Innovation Australia (TIA). TIA is supported by the Australian Government through the National Collaborative Research Infrastructure Strategy program.